Supernus to Present at the 2018 Cowen Health Care Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/28/2026

1. WDAY
2. ESTC
3. MRVL
4. AFRM
5. RBRK

6. S
7. DG
8. ULTA
9. NVDA
10. GAP

Get Alerts SUPN Hot Sheet

Price: $43.54 -1.47%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

ROCKVILLE, Md., March 06, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update for the Company, and host investor meetings, at the Cowen 38th Annual Health Care Conference.

Date: Tuesday, March 13, 2018Time: 10:00 a.m. ETPlace: The Boston Marriott Copley Place, Boston, Mass.

Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investor Relations Section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company's website.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine headache and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.

CONTACT:Jack A. Khattar, President and CEOGregory S. Patrick, Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591

Investor Contact:Peter VozzoWestwicke PartnersOffice: (443) 213-0505Mobile: (443) 377-4767Email: [email protected]